A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Exclusion Criteria

• •Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings suggestive of UC.
• •Subjects diagnosed with Crohn's disease but without previous exposure to treatment (i.e., treatment-naïve).
• •Subjects receiving the following treatment for Crohn's disease:
• •Azathioprine, 6-mercaptopurine or methotrexate within 2 weeks prior to baseline.
• •Anti-TNFα therapy within 8 weeks prior to baseline.
• •Interferon therapy within 8 weeks prior to baseline.
• •Cyclosporine, mycophenolate, or tacrolimus within 4 weeks prior to baseline.
• •Intravenous corticosteroids within 2 weeks prior to baseline.